Clinical data | |
---|---|
Pronunciation | /ˌætəˈzænəvɪər/ AT-ə-ZAN-ə-veer[1] |
Trade names | Reyataz, Evotaz, others[2] |
AHFS/Drugs.com | Monograph |
MedlinePlus | a603019 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 60-68% |
Protein binding | 86% |
Metabolism | Liver (CYP3A4-mediated) |
Elimination half-life | 6.5 hours |
Excretion | Fecal and kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
NIAID ChemDB | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.243.594 |
Chemical and physical data | |
Formula | C38H52N6O7 |
Molar mass | 704.869 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Atazanavir, sold under the brand name Reyataz among others, is an antiretroviral medication used to treat HIV/AIDS.[2] It is generally recommended for use with other antiretrovirals.[2] It may be used for prevention after a needlestick injury or other potential exposure (postexposure prophylaxis (PEP)).[2] It is taken by mouth.[2]
Common side effects include headache, nausea, yellowish skin, abdominal pain, trouble sleeping, and fever.[2] Severe side effects include rashes such as erythema multiforme and high blood sugar.[2] Atazanavir appears to be safe to use during pregnancy.[2] It is of the protease inhibitor (PI) class and works by blocking HIV protease.[2]
Atazanavir was approved for medical use in the United States in 2003.[2] It is on the World Health Organization's List of Essential Medicines.[9] It is available as a generic medication.[10]